Grifols acquires control over a Swiss and Australian group through a €25 million investment

Barcelona, 3 March, 2009. A total €25 million transaction was carried out through a capital increase in a Swiss and Australian group. With the signing of the agreement, Grifols acquires 49% of the capital stock and gains full control of the group. The investment will be carried out through a holding company with three differentiated areas of activity.

Firstly, a new Australian company will give Grifols the commercial strength it needs to reaffirm and expand its presence in the diagnostics market in Australia and New Zealand, which until now has focused on selling instruments through distributors.

The acquisition also allows Grifols to explore other possibilities that do not exclude further industrial investments utilizing Grifols Engineering technology.

Secondly, with the obtainment of the license for Flebogamma DIF in Australia, Grifols will begin to sell this biological product during the first quarter of the year, thus initiating the commercialization of Grifols hemoderivatives in this country.

Lastly, Grifols has also invested in the purchase, under the same conditions, of Medion Diagnostics AG, a company located in Switzerland that has developed an exciting new technology in blood group serology complementing and enhancing the existing Grifols product line. This additional line of products will give the company the most complete and advanced range of products for blood typing and pretransfusion diagnostics, with the high level of automation, safety and productivity that the sector requires. The two companies have agreed to invest in the final development of this new and revolutionary technology.

Every market in which the company operates will benefit from the availability of new products manufactured in Switzerland, and most especially the US market, since some of the products are already FDA-approved. All of the foregoing, this will make it possible for the company to accelerate the development of its Diagnostic Division in the United States.

With this transaction, Grifols continues to consolidate in Asia-Pacific markets, where it now has its own subsidiaries in Singapore, Malaysia and Thailand, in addition to a representation office in Japan.

In the words of Ramon Riera, commercial vice president of Grifols: “With the establishment of a presence in the US, and after having significantly enhanced the production of biological products, the company is now focusing on increasing its market share in the countries of Latin America where it has been present for more than 15 years (Argentina, Chile, Mexico and Brazil) and in Asia. China is also part of this new phase. We have had to wait to have a sufficient
market share in the US and to boost production. In addition, this move also
demonstrates Grifols’ commitments to its Diagnostic Division. Our Barcelona
plant has just increased threefold its production capacity of DG Gel cards for
immunohematology”.

The investment is expected to have approximately EURO 20 million in revenue
in 2009, and to double this amount in the coming three years.

Osborne & Clarke of Barcelona were responsible for all of the planning for this
transaction as well as for executing it.

About Grifols

Grifols is a Spanish holding company specialized in the pharmaceutical-hospital sector and is
present in more than 90 countries. Since 2006, the company has been listed on the Spanish
Continuous Market and forms part of the Ibex-35. Currently it is the first company in the
European sector in plasma derivatives and the fourth in production worldwide. In upcoming
years, the company will strengthen its leadership in the industry as a vertically integrated
company, thanks to recent investments and those which will be carried out in 2008-2012,
representing 400 million euros. In terms of raw materials, Grifols has ensured its plasma supply
with 80 plasmapheresis centers in the United States and in terms of fractionation, its plants in
Barcelona (Spain) and Los Angeles (United States) will allow the company to respond to the
growing market demand. Nevertheless, the company is preparing for sustained growth in the
following 8-10 years and has launched an ambitious investment plan.